MXPA05001222A - Conjugados de compuestos de porfirina con agentes quimioterapeuticos. - Google Patents

Conjugados de compuestos de porfirina con agentes quimioterapeuticos.

Info

Publication number
MXPA05001222A
MXPA05001222A MXPA05001222A MXPA05001222A MXPA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A MX PA05001222 A MXPA05001222 A MX PA05001222A
Authority
MX
Mexico
Prior art keywords
porphyrin
compound according
chemotherapeutic agent
group
doxorubicin
Prior art date
Application number
MXPA05001222A
Other languages
English (en)
Spanish (es)
Inventor
Laurence J Marton
Original Assignee
Cellgate Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellgate Inc filed Critical Cellgate Inc
Publication of MXPA05001222A publication Critical patent/MXPA05001222A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA05001222A 2002-08-02 2003-07-30 Conjugados de compuestos de porfirina con agentes quimioterapeuticos. MXPA05001222A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40051202P 2002-08-02 2002-08-02
PCT/US2003/023898 WO2004012774A1 (en) 2002-08-02 2003-07-30 Conjugates of porphyrin compounds with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
MXPA05001222A true MXPA05001222A (es) 2005-09-12

Family

ID=31495832

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05001222A MXPA05001222A (es) 2002-08-02 2003-07-30 Conjugados de compuestos de porfirina con agentes quimioterapeuticos.

Country Status (7)

Country Link
US (1) US20040192665A1 (enExample)
EP (1) EP1525001A1 (enExample)
JP (1) JP2005539011A (enExample)
AU (1) AU2003257055A1 (enExample)
CA (1) CA2494214A1 (enExample)
MX (1) MXPA05001222A (enExample)
WO (1) WO2004012774A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066587A2 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Polyamines and their use in therapy
WO2002091989A2 (en) 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
EP1515973A1 (en) * 2002-06-26 2005-03-23 Cellgate Inc. Porphyrin-polyamine conjugates for cancer therapy
FR2867189A1 (fr) * 2004-03-08 2005-09-09 Ludovic Bourre Nouveaux composes medicamenteux destines au traitement des pathologies dependantes de l'activite proteine kinase
CA2573927A1 (en) 2004-07-15 2006-01-19 The University Of Sydney Porphyrin linked metronidazole against gum disease: porphyromonas gingivalis
EP2599497A3 (en) * 2008-09-08 2013-09-25 Hoffman/Barrett, L.L.C. Porphyrazine-chemotherapeutic agents conjugates
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
PT3149025T (pt) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
CA3028122A1 (en) 2016-06-16 2017-12-21 Oncoselect Therapeutics, Llc Porphyrin compounds and compositions useful for treating cancer
EP3638248A4 (en) 2017-06-16 2021-06-30 The Regents of The University of California CONJUGATES OF PHARMACEUTICAL INGREDIENTS
US11339192B2 (en) 2017-10-04 2022-05-24 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
US11576946B2 (en) 2018-01-29 2023-02-14 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-NFAT interaction
EP3746105A4 (en) 2018-01-29 2022-05-18 Ohio State Innovation Foundation CYCLIC PEPTIDYLIN HIBITORS OF THE CAL-PDZ-BINDING DOMAIN
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
CN108409756B (zh) * 2018-03-08 2019-12-10 莎穆(上海)生物科技有限公司 一种基于喜树碱类的异二聚体多功能前药及其制备方法和应用
CN119504769B (zh) * 2024-10-21 2025-09-30 高博药业有限公司 一种靶向her2的抗体偶联金(ⅲ)卟啉药物及其合成与肿瘤治疗应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435087A1 (de) * 1994-09-30 1996-04-04 Deutsches Krebsforsch Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5677350A (en) * 1995-06-07 1997-10-14 Wisconsin Alumni Research Foundation Inhibition of cancer cell growth, proliferation, and metastasis using N,N'-dα,ω-diaminoalkanes
FR2764605B1 (fr) * 1997-06-17 2004-03-26 Univ Hyderabad Molecules hybrides d'un photosensibilisateur et d'un agent chimiotherapeutique, leur procede de production et leur application collaterale en chimiotherapie et therapie photodynamique
US5889061A (en) * 1997-10-15 1999-03-30 Wisconsin Alumni Research Foundation Conformationally restricted polyamines
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
CA2334809A1 (en) * 1998-06-05 1999-12-09 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
WO2001028592A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
WO2002096417A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
EP1515973A1 (en) * 2002-06-26 2005-03-23 Cellgate Inc. Porphyrin-polyamine conjugates for cancer therapy

Also Published As

Publication number Publication date
JP2005539011A (ja) 2005-12-22
CA2494214A1 (en) 2004-02-12
EP1525001A1 (en) 2005-04-27
US20040192665A1 (en) 2004-09-30
WO2004012774A1 (en) 2004-02-12
AU2003257055A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
US20040192665A1 (en) Conjugates of porphyrin compounds with chemotherapeutic agents
Renner et al. Recent progress in the syntheses and biological evaluation of boronated porphyrins for boron neutron-capture therapy
US20240042045A1 (en) Nanoparticles containing multiple cleavable produgs for cancer therapy
US6207660B1 (en) Texaphyrin conjugates and uses thereof
US20020049155A1 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
EP3638367A1 (en) Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
JP2001501596A (ja) バイオコンジュゲートおよび生物学的活性剤の送達
US20050249663A1 (en) Coadministration of transport protein with conjugated cobalamin to deliver agents
CN1390143A (zh) 两亲型前药
ES2428088T3 (es) Derivados de camptotecina como agentes quimioradiosensibilizadores
JP2003512338A (ja) 造影剤および抗腫瘍薬として有用なコバラミン結合体
CN112245591A (zh) 化疗药物-低氧激活前药一体化前药自组装纳米粒的构建
US7026347B2 (en) Porphyrin-polyamine conjugates for cancer therapy
US20230149546A1 (en) Photosensitizer conjugated gold nanoparticles for radiotherapy enhancement
CN1741801B (zh) 水溶性阴离子型细菌叶绿素衍生物及其用途
CN113230417A (zh) 葡萄糖和三苯基鏻修饰的脑肿瘤靶向脂质体的制备与应用
JP5372371B2 (ja) カチオン性バクテリオクロロフィル誘導体及びその使用
US20040047917A1 (en) Drug delivery and targeting with vitamin B12 conjugates
US20090318370A1 (en) Novel glycoconjugated chlorin derivatives and method of producing the same
Verschuere et al. Enhancing anti-tumor immunity through intratumoral combination therapy with amphiphilic conjugates of oxaliplatin and imidazoquinoline TLR7/8 agonist
EP2216049A1 (en) Drug conjugates with polyglycerols
EP3442979A1 (en) Topoisomerase poisons
KR20250090018A (ko) 면역항암제가 결합된 금속-유기 골격체를 포함하는 항암용 조성물 및 이의 용도
AU2002330153B2 (en) Coadministration of transport protein with conjugated cobalamin to deliver agents
AU2006201021A1 (en) Cobalamin conjugates useful as imaging agents and as antitumor agents